Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Decline in Short Interest

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) saw a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 1,600 shares, a decrease of 97.5% from the January 31st total of 65,000 shares. Based on an average daily volume of 440,900 shares, the days-to-cover ratio is currently 0.0 days.

Daiichi Sankyo Price Performance

Shares of OTCMKTS DSNKY opened at $22.95 on Friday. The stock’s 50-day moving average is $26.22 and its two-hundred day moving average is $31.17. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.77 and a quick ratio of 2.11. Daiichi Sankyo has a 1-year low of $22.47 and a 1-year high of $42.48. The company has a market cap of $43.80 billion and a price-to-earnings ratio of 26.69.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, January 31st. The company reported $0.22 earnings per share for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. Analysts forecast that Daiichi Sankyo will post 0.73 EPS for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.